🇺🇸 FDA
Patent

US 12291709

Compositions and methods for modulating apolipoprotein (a) expression

granted A61KA61K31/7088A61K31/713

Quick answer

US patent 12291709 (Compositions and methods for modulating apolipoprotein (a) expression) held by Ionis Pharmaceuticals, Inc. expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/7088, A61K31/713, A61K47/549, A61K47/59